Deadline: 04-Oct-2025
Entries are now open for Antimicrobial Stewardship (AMS), a key objective of the WHO Global Action Plan on Antimicrobial Resistance (AMR), which promotes the appropriate use of antimicrobials to improve patient outcomes and reduce resistance. The initiative aims to address gaps and challenges in deploying antibiotic therapies in Africa, including regulatory, systemic, and patient care issues, as well as the future of antibiotic research and development. It also explores the role of small-molecule therapeutics in combating AMR.
Proposed projects should focus on interventions or strategies that strengthen AMS practices in healthcare and community settings, reinforce regulatory bodies and health systems to develop centralized AMS support structures, improve access to and rational use of antibiotics, enhance AMR surveillance and data sharing, and advance diagnostic technologies for evidence-based treatment. Other priorities include reinforcing AMR research and innovation, addressing gaps in clinical practice guidelines, promoting sustainable antibiotic production and supply, developing standardized metrics to evaluate AMS interventions, and fostering co-creation models between patients and healthcare providers, particularly in rural and underserved communities.
In partnership with Pfizer, the International Society for Infectious Diseases (ISID) invites organizations and individuals working on AMR in Africa to submit grant proposals. Projects may request up to $100,000, with a total budget of $400,000 to be distributed among 4–6 recipients over two years.
The target audience is multidisciplinary, involving healthcare professionals, public health authorities, policymakers, researchers, hospital administrators, regulatory agencies, community health workers, and the public. Applicants must be based in Sub-Saharan Africa, with initiatives operating at the regional, sub-regional, or national level. Eligible applicants include academic and research institutions, intergovernmental organizations, regional communities, scientific associations, NGOs, and other entities with a proven commitment to AMR.
Collaboration is strongly encouraged, with preference for proposals involving meaningful partnerships with universities, hospitals, healthcare systems, public health institutions, or professional societies. Both intra-institutional and inter-institutional partnerships are welcome, provided all partners have clearly defined roles and the lead applicant plays a central role in project design and implementation. Grassroots organizations with a strong track record, particularly those serving vulnerable populations in Sub-Saharan Africa, will receive priority.
For more information, visit Pfizer.
